minoxidil topical (OTC)

Brand and Other Names:Rogaine, Women's Rogaine
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

topical solution

  • 2%
  • 5%

topical foam

  • 5%

Androgenetic Alopecia

Male: Apply 1 mL of 2% or 5% solution to affected areas of scalp q12hr (qAM & qHS); no more than 2 mL in 24 hours

Female: Apply 1 mL of 2% solution or 5% foam to affected areas of scalp q12hr (qAM & qHS)

Hair growth may require 4 months of therapy

Safety and efficacy not established

Next:

Adverse Effects

Frequency Not Defined

Irritation

Eczema

Hypertrichosis

Allergic contact dermatitis

Local erythema

Exacerbation of hair loss

Burning

Respiratory infections

Tendinitis

Back pain

Fractures

Sinusitis

Edema

Anxiety

Erythema at site of application

May see systemic effects (hypotension)

Dizziness

Lightheadedness

Faintness

Previous
Next:

Warnings

Contraindications

Hypersensitivity to drug or components

Cautions

Once started, need to use indefinitely; hair growth should be apparent by 4 months

Do not apply to other parts of body

Can be easily removed from scalp; avoid contact with scalp once applied

Use caution in patients with heart disease

Solution is flammable; keep away from fire or flame

Avoid contact with eyes; in accidental contact with eyes, rinse eyes with large amounts of cool tap water

Not for use when infection, redness, inlfammation present

Changes in hair color and texture reported

Product will not work for everyone

Not for use if degree of hair loss is different from carton; product may not be for you

Do not use if hair loss is sudden and/or patchy or there is no family history of hair loss or hair loss is associated with childbirth

Not for use if reason for hair loss is not known, or patient is under 18 years of age, or if scalp is red, infected, inflamed, painful or irritated

Do not use other medicines on scalp

Discontinue use and see healthcare professional if scalp irritation or redness occurs, hands or feet swell, unwanted facial hair growth occurs, sudden and unexplaised weight gain occur, or if hair regrowth does not occur in 4 months

Previous
Next:

Pregnancy & Lactation

Pregnancy Category: C

Lactation: Following topical application of the drug is not known, but the drug has been shown to distribute into milk following oral administration in lactating women

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Acts at the level of the hair follicle, possibly involving direct stimulation of hair follicle epithelial growth; may increase cutaneous blood flow, and stimulate resting hair follicles

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.